{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-129524","form_type":"8-K","ticker":"NTLA","cik":"0001652130","company_name":"Intellia Therapeutics, Inc.","filed_at":"2025-05-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.211696+00:00","generated_at":"2026-05-20T08:14:28.056185+00:00","sec_items":["7.01","8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Intellia Therapeutics provides Phase 3 updates for NTLA-2002 and nex-z studies","bullets":["HAELO study enrollment on track; expect completion Q3 2025, BLA submission H2 2026, potential US launch 2027.","MAGNITUDE-2 study of nex-z for ATTRv-PN progressing; BLA submission by 2028, potential US launch 2029.","MAGNITUDE study for nex-z in ATTR-CM enrolled ~365 of 765 patients; enrollment completion expected early 2027.","Over 200 patients dosed with nex-z in MAGNITUDE; adverse events similar to Phase 1; one asymptomatic grade 4 liver elevation resolving."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-129524","json":"https://secwatch.observer/filing/0001193125-25-129524.json","markdown":"https://secwatch.observer/filing/0001193125-25-129524.md","text":"https://secwatch.observer/filing/0001193125-25-129524.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652130/000119312525129524/0001193125-25-129524-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652130/000119312525129524/d40487d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-20T08:14:28.056185+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}